Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Liverpool is leading a major new international project to improve our understanding of severe coronavirus infection in humans, together with collaborators from the University of Oxford, Public Health England, the University of Bristol; A*STAR in Singapore; and King Fahd Medical City in Saudi Arabia.

3D illustration of virus cells

Researchers will sequence and analyse samples from humans and animals to create profiles of various coronaviruses, including SARS-CoV-2, which causes COVID-19. The results will help inform the development of new treatments and vaccines to tackle coronavirus infections.

The U.S. Food and Drug Administration (FDA) has awarded $5,402,198 (£4,155,536) to support the initial three-year project.

The emergence of SARS-CoV-2 in 2019 and the associated COVID-19 pandemic, and prior SARS-CoV and MERS-CoV outbreaks, demonstrate the significant threat posed by coronaviruses. Since there are currently no licensed therapeutics or vaccines to prevent or treat infections from these specific viruses or coronaviruses in general, there is an urgent need to support development and evaluation of relevant medical countermeasures.

The full story is available on the University of Oxford website

Similar stories

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.

Overusing antibiotics? Find out with Antibiotic Footprint Calculator

To help reduce the overuse of antibiotics, Oxford researchers today released a new, easy to use online tool – Antibiotic Footprint Calculator – that could make an important contribution in the fight against antimicrobial resistance (AMR), one of the world’s most significant emerging threats to public health.

$2m fund awarded for Oxford’s single-cell ancestry vaccine research

The University of Oxford is to benefit from $2 million (£1.49 million) in funding from the Chan Zuckerberg Initiative (CZI) to investigate how our ancestry and diversity influence the way that vaccines work in our cells.